Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions

About this update from Novo Nordisk A/s Class B

PLAINSBORO, NJ and BAGSVÆRD, Denmark, May 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association® (ADA), taking place in New Orleans, June 5–8, 2026. Phase 3 REIMAGINE 1–3 results evaluating the effects of investigational CagriSema on glycemic control and weight loss across a range of type 2 diabetes background therapies will be featured in a symposium.1 A total of 40 abstracts will be presented, including phase 2 data assessing the safety and efficacy of investigational once-weekly injectable zenagamtide, as well as new data for Ozempic® and Wegovy® building on the growing body of clinical evidence for semaglutide across multiple cardiometabolic conditions.2 "The ADA's 2026 Scientific Sessions underscores the breadth and strength of our approach to cardiometabolic diseases. From amylin-based pipeline candidates to continued expansion of our portfolio, we are building on the established and unique profile of semaglutide," said Martin Lange, executive vice president of Research & Development and chief scientific officer at Novo Nordisk. "As pioneers in this space, we remain focused on advancing innovation that can meaningfully improve the lives of millions living with serious chronic diseases." On Sunday, June 7, 2026, Novo Nordisk will host an R&D investor event on the science and abstracts presented at the conference. The event will be accessible via a live webcast on the Novo Nordisk investor website. Select Novo Nordisk abstracts to be presented at The ADA's 2026 Scientific Sessions, June 5 – 8, New Orleans: Data for investigational uses of semaglutide and investigational medicines containing CagriSema, zenagamtide, IcoSema, and efruxifermin. Symposium: Novo Nordisk poster and oral presentations: CagriSema Zenagamtide Wegovy® (semaglutide injection and tablets) Ozempic® (semaglutide injection and tablets) Semaglutide for MASH Insulin Icodec IcoSema Efruxifermin Cross-product Non-product 9 additional abstracts being presented at ADA will cover data related to cardiometabolic diseases including type 2 diabetes, obesity, kidney, and liver disease. CagriSema, zenagamtide, IcoSema, and efruxifermin are not approved in the United States. Safety and efficacy are not est...

View stock analysis, news, and events for Novo Nordisk A/s Class B